Drug Database
PA

pancreatin + Aspergillus oryzae enzyme concentrate (Combizyme forte / Combizym / Combizym composto)

✓ Approved

Daiichi Sankyo Company Limited · PNLIP

What is pancreatin + Aspergillus oryzae enzyme concentrate?

pancreatin + Aspergillus oryzae enzyme concentrate is a therapeutic agent developed by Daiichi Sankyo Company Limited. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesCombizyme forte, Combizym, Combizym composto
CompanyDaiichi Sankyo Company Limited
Molecular TargetPNLIP
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Daiichi Sankyo Company Limited

Mechanism of Action

Molecular Targets

pancreatin + Aspergillus oryzae enzyme concentrate acts on 1 molecular target:

PNLIPpancreatic lipase (PL, PNLIPD)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

pancreatin + Aspergillus oryzae enzyme concentrate is developed for 2 unique indications across 1 therapeutic area.

Therapeutic AreaConditionPhase
Gastrointestinal disordersDyspepsia✓ Approved
Gastrointestinal disordersFlatulence✓ Approved

Related Research Articles

PubMedThe plant pathology journal2026-11-11

Molecular Differentiation of Bipolaris oryzae and Nigrospora oryzae Associated with Brown Spot Symptoms in Rice.

Kim Seoyeon S, Chung Hyunjung H, Kang Chawoon C, An Sunmin S et al.

Rice brown spot is primarily associated with Bipolaris oryzae; however, Nigrospora oryzae can also be recovered from rice leaves exhibiting similar symptoms, complicating their differentiation based on field symptoms alone. In this study, the temporal occurrence of these fungi was investigated in symptomatic rice leaves collected during the 2024 and 2025 growing seasons, and molecular assays were developed for their rapid discrimination. B. oryzae predominated during the early to mid-growing season, whereas the relative frequency of N. oryzae increased during later sampling periods. Sequence comparisons were used to develop primer sets targeting ITS, TEF1, and GAPDH for B. oryzae and ITS, TEF1, and TUB2 for N. oryzae. The primers preferentially amplified their corresponding target species in conventional and real-time PCR assays. Validation using additional field isolates revealed weak non-target amplification with some primer sets in conventional PCR, whereas real-time PCR provided clear quantitative separation between target and non-target isolates, with ΔCq values ranging from 9.9 to 15.8. These results demonstrate temporal changes in the relative occurrence of B. oryzae and N. oryzae on symptomatic rice leaves and indicate that real-time PCR provides a useful molecular approach for differentiating the two fungi. The developed assays may facilitate further investigation of their seasonal occurrence and association with brown spot symptoms in rice.

PMID 43010138
Read full article →
PubMedAfrican journal of laboratory medicine2026-11-11

Prevalence of serum Aspergillus galactomannan positivity among immunocompromised patients with suspected invasive aspergillosis at a tertiary care hospital.

Devnani Monika M, Pathan Nazneen N, Sharma Malvika M, Vyas Aruna A et al.

Invasive aspergillosis (IA) is a major opportunistic fungal infection in immunocompromised patients. Serum Aspergillus galactomannan (GM) is an adjunctive marker in suspected IA. To determine the prevalence of serum GM positivity and associated risk factors among immunocompromised patients with clinical suspicion of IA. A cross-sectional observational study was conducted among 200 immunocompromised patients clinically suspected of IA at a tertiary hospital in Jaipur, India, from July 2023 to December 2023. Serum GM was tested using the Platelia™ Aspergillus GM enzyme immunoassay. Index values < 0.50 were considered negative, ≥ 0.50 positive, and 0.45-0.49 borderline. Demographic and clinical risk factors were recorded from clinical and laboratory records and analysed using chi-square test and multivariate regression. Among 200 patients, 98 (49.0%) were GM positive, 92 (46.0%) negative, and 10 (5.0%) borderline. On multivariate analysis, neutropenia was the strongest independent predictor of GM positivity, followed by tuberculosis and lung disease. HIV infection was more frequent among GM positive patients but was not independently associated after adjustment. Serum GM positivity was high among immunocompromised patients with clinically suspected IA. Neutropenia was the strongest independent predictor of GM positivity, while tuberculosis and lung disease were also independently associated. Serum GM may aid evaluation when interpreted with clinical, radiological and microbiological findings. As confirmatory methods were not available for all patients, this study does not establish diagnostic accuracy of the assay. This study provides data on the prevalence of serum GM positivity among immunocompromised patients with suspected IA in Rajasthan, India. Neutropenia, tuberculosis and chronic lung disease were independently associated with GM positivity, supporting the use of serum GM assay in high-risk patients.

PMID 43010973
Read full article →
PubMedCurrent medicinal chemistry2026-11-11

Natural and Synthetic Dihydroorotate Dehydrogenase Inhibitors for Therapeutic Applications.

Sures Prema Losihini PL, Tan Chze-Yin CY, Choo Yeun-Mun YM

Dihydroorotate Dehydrogenase (DHODH) is an important mitochondrial enzyme that plays a key role in the catalysis of an important step in de novo pyrimidine biosynthesis, which in turn supports DNA and RNA production. This enzyme is highly conserved across different organisms, including humans, protozoan parasites, and bacteria, although subtle differences in its structure make it possible to selectively inhibit this enzyme. In recent years, this enzyme has emerged as a promising target in the development of therapeutic agents against different diseases, including cancer, autoimmune diseases, and malaria. Various natural and synthetic compounds have shown promise as inhibitors of this enzyme. While natural inhibitors such as lapachol (1), piperine (5), and baicalein (6) provide a starting point in terms of chemical structure, synthetic inhibitors such as GSK983 (20), Brequinar (21), Teriflunomide (22), Vidofludimus (35), BAY 2402234 (36), and Tenovin (40) achieve high potency and specificity against the human enzyme. In the context of malaria treatment, selective inhibitors such as DSM265 (37), DSM267 (38), and DSM421 (39) selectively inhibit Plasmodium falciparum DHODH with minimal cross-reactivity to the human enzyme. This review outlines the conservation and variability in the structure of this enzyme in different organisms, and the mode of interaction with inhibitors, as well as the different strategies that have been adopted to develop potent and selective inhibitors of this enzyme with minimal side effects in the context of cancer, autoimmune diseases, and malaria treatment.

PMID 43012291
Read full article →
PubMedTrials2026-11-11

Fibrinogen Early In Severe Trauma studY II (FEISTY II): study protocol for a randomised clinical trial of fibrinogen concentrate vs cryoprecipitate in traumatic haemorrhage in Australia and New Zealand.

Winearls James J, Ady Bridget B, Balogh Zsolt J ZJ, Burns Brian B et al.

Haemorrhage is a leading cause of preventable death amongst severe trauma patients and is often complicated by hypofibrinogenaemia. Fibrinogen replacement can be achieved using fibrinogen concentrate (FC) or Cryoprecipitate (Cryo), but comparative evidence in traumatic haemorrhage is limited. To determine, in trauma patients with major haemorrhage and hypofibrinogenaemia, whether fibrinogen replacement using FC compared to Cryo increases the number of days alive and out of hospital (at home) within the first 90 days after randomisation (DAOH90). The Fibrinogen Early In Severe Trauma studY II (FEISTY II) is a phase III, multi-centre, randomised, two-arm parallel, open-label, superiority trial comparing FC and Cryo for fibrinogen replacement in severely injured trauma patients with major haemorrhage and hypofibrinogenaemia. Inclusion criteria are adults (≥ 18 years) affected by trauma and judged to have significant active haemorrhage with FIBTEM A5 ≤ 10 mm, TEG FF A10 ≤ 15 mm or FibC ≤ 2 g/L, for whom the local Major Haemorrhage Protocol (MHP) has been activated and/or emergency blood products have been transfused. Exclusion criteria are injuries judged incompatible with survival, inability to randomise within 6 h of trauma centre admission, pregnancy, objection to blood products, genetic or acquired coagulation disorder, dedicated fibrinogen replacement prior to randomisation, participation in competing study, and pre-existing co-morbidity that may interfere with the assessment of outcome. Patients will be block randomised 1:1 and stratified by site and clinical suspicion of Traumatic Brain Injury. The primary outcome is DAOH90. Secondary outcomes include all-cause mortality, transfusion requirements and measures of functional recovery and quality of life. Safety data will include symptomatic deep vein thrombosis (DVT) and pulmonary embolism (PE), myocardial infarction (MI), ischaemic stroke and transfusion reactions. A total of 900 patients will be recruited by trauma centre clinical staff across 23 trauma centres in Australia and New Zealand. The optimal approach to fibrinogen replacement in traumatic haemorrhage remains uncertain. FEISTY II is a multi-centre randomised clinical trial in severely injured bleeding trauma patients, comparing FC to Cryo in terms of efficacy, safety, and cost-effectiveness. ClinicalTrials.gov.  NCT05449834 . Registered on 08 July 2022. 1st Participant enrolled 21 November 2022.

PMID 43010006
Read full article →
PubMedMedComm2026-11-11

Neutrophil Extracellular Traps: From Mechanistic Insights to Therapeutic Targeting.

Fan Hongjie H, Tong Yurui Y, Tang Bufu B, Hu Jihong J et al.

Neutrophils represent the most abundant leukocytes in circulation and serve to protect the host from infection. Paradoxically, they also contribute to cancer by releasing extracellular traps known as neutrophil extracellular traps (NETs). These structures exert opposing effects on tumors, either promoting progression or suppressing growth, depending on the specific context. However, a comprehensive framework reconciling these dual roles is lacking. NETs can be reconceptualised as multimodal signal processors within the tumor microenvironment, with a primary focus on cancer while acknowledging relevance to certain inflammatory and autoimmune conditions. NETs function through three interconnected modalities: (1) biomechanical scaffolds that remodel tissue architecture via integrin-focal adhesion kinase (FAK) mechanotransduction; (2) immunometabolic hubs that drive glycolytic reprogramming and immune suppression; and (3) signal-integration platforms that concentrate oncogenic cues for synergistic pathway activation. This systems-level perspective, orchestrated by nodes such as hypoxia-inducible factor 1-alpha and integrin-FAK, elucidates how microenvironmental inputs dictate NET phenotypic polarity. Furthermore, therapeutic implications are addressed, including biomarker-guided stratification, optimal intervention timing during the perioperative period, dormancy phase, immunotherapy combinations, and strategies to disrupt modal crosstalk while preserving essential host defence. Future priorities include resolving NET heterogeneity and developing localised delivery systems. This roadmap enhances precision targeting of NETs in oncology and other fields.

PMID 43011339
Read full article →
PubMedChaos (Woodbury, N.Y.)2026-11-11

A spatiotemporal ecological-epidemiological model for malaria-borne mosquito control.

Alon Lee-Or LO, Lazebnik Teddy T

Malaria remains one of the world's most persistent infectious diseases, driven by complex interactions among human mobility, vector ecology, and environmental heterogeneity. Because mosquito larvae concentrate in aquatic habitats, biological control using larvivorous fish has long been used as a sustainable complement to insecticides. However, introducing predatory fish creates a central ecological trade-off where the same intervention that suppresses mosquito emergence also disrupts native aquatic communities. Addressing this concern, we develop a spatiotemporal eco-epidemiological framework that links vector-borne human pandemic spread, mosquito population movement and reproduction dynamics, and two interacting fish populations in which one intervention fish is introduced to consume larvae, and a native fish population is to be conserved. Within this framework, we compare a one-time offline deployment strategy with a dynamic monitoring strategy that updates fish release in response to local system states. Our results identify conditions under which adaptive deployment achieves a better balance between reducing human infections and preserving native fish, offering a principled basis for ecologically informed malaria control in heterogeneous urban landscapes. Quantitatively, both the offline and the monitoring strategy avert roughly two-thirds of the no-intervention infection burden and differ only modestly in epidemiological outcome. The monitoring strategy attains comparable infection control at a lower native-fish loss.

PMID 43012645
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about pancreatin + Aspergillus oryzae enzyme concentrate